Clinical trials: 5-FU
Colon Cancer, Rectal Cancer
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
This is a prospective, multicentre, cohort study. For cohort 1(CGA cohort), experimental cohort, older or Frail patients with metastatic colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive…
- Trial name
- NCT06665087
- Testing
- Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody
- Volunteers
- 110 people
- Sponsor
- Fudan University
Colorectal Cancer
S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more cancer cells.
- Trial name
- NCT00002593
- Testing
- fluorouracil, leucovorin calcium, levamisole hydrochloride
- Where
- 60 sites in United States, Canada and 2 more
- Volunteers
- 1,135 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer Stage IV
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
This is a single-arm, phase II study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of apatinib and two-drug chemotherapy (S-1 plus nab-paclitaxel) as conversion therapy in patients…
- Trial name
- NCT04267549
- Testing
- sintilimab, apatinib, S1
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
Hepatic artery infusion chemotherapy (HAIC) is a locoregional therapy commonly used in hepatocellular carcinoma (HCC), with high response rates and minimal impairment of liver function reported.
- Trial name
- NCT06632717
- Testing
- Cisplatin, 5-fluorouracil, Lipiodol embolization
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Breast Neoplasms
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor…
- Trial name
- NCT01779050
- Testing
- Doxorubicin, Trastuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00006015
- Testing
- trastuzumab, fluorouracil, leucovorin calcium
- Where
- 47 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
- Trial name
- NCT06363825
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fujian Medical University
Liver Metastases, Colorectal Cancer
Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer
A multi-center, non-random, open study ,to observe efficacy and safety of bevacizumab plus Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously untreated unresectable liver metastases from…
- Trial name
- NCT01763450
- Testing
- bevacizumab plus chemotherapy
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
To evaluate efficacy and safety of irinotecan hydrochloride liposome in combination with 5-FU/LV as second-line treatment for locally advanced or metastatic pancreatic cancer after treatment failure with gemcitabine-based therapy.
- Trial name
- NCT05074589
- Testing
- Irinotecan liposome、5-Fluorouracil、Leucovorin
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
This is an open-label, Phase II, single-stage study evaluating the use of panitumumab, paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal adenocarcinoma.
- Conditions
- Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Adenocarcinoma of the Proximal Stomach
- Trial name
- NCT01182610
- Testing
- Panitumumab, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Accelerated Community Oncology Research Network
Resected Pancreatic Adenocarcinoma
Study of Proton Therapy in Adjuvant Pancreatic Cancer
This trial aims to determine a safe schedule of short-course proton beam radiation therapy with adjuvant mFOLFIRINOX for patients with resected pancreatic adenocarcinoma.
- Trial name
- Proton-PANC (NCT03885284)
- Testing
- mFOLFIRINOX, Proton beam radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rectal Cancer
Planned Non-operative Management for Rectal Cancer
The investigators propose to conduct an observational study on consecutive patients with low-lying or mid rectal cancers smaller than 5 cm in length and less than 50% of rectal circumferential extent.
- Trial name
- NCT05241574
- Testing
- Radiotherapy boost, Additional consolidation chemotherapy
- Where
- Poland
- Volunteers
- 23 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene
Gastric Adenocarcinoma
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
In previous studies,the investigators found that POF (A combination of oxaliplatin, fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in patients with advanced gastric cancer.
- Trial name
- NCT03788174
- Testing
- Apatinib, POF
- Where
- 2 sites in China
- Volunteers
- 26 people
- Sponsor
- Fujian Cancer Hospital
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02890355
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 783 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Appendiceal Cancer
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer
This study is a prospective, multi-center, open-label phase I trial designed to determine the maximun tolerated dose of IP oxaliplatin when given in combination with mFOLFIRI.
- Conditions
- Colorectal Cancer, Appendiceal Cancer, Peritoneal Carcinoma
- Trial name
- IPOX-FOLFIRI (NCT04158349)
- Testing
- Oxaliplatin, mFOLFIRI
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.